Physician

Ibrahim Ebada Sadek, M.D.

According to 2025 Medicare claims, Ibrahim Sadek, M.D. (NPI: 1457672685) practices medical oncology in the Orlando-Kissimmee-Sanford, FL market, with the plurality of this provider's patient population coming from Lake, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32163-2040.

Sadek's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,560 traditional Medicare patients, billed 310,781 HCPCS/CPT codes, and received $4,343,672 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,234 prescription claims across 323 beneficiaries totaling $4,461,236 in drug costs, led by Revlimid (Lenalidomide). 2019 DME data shows 28 claims. Open Payments data shows 171 records totaling $3,895. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $9,224 to $4,343,672. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,733 to $4,461,236. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	61	125	$9,224
2018	189	733	$58,727
2019	286	1,007	$79,507
2020	280	3,955	$71,950
2021	295	127,411	$2,106,033
2022	800	223,882	$2,749,236
2023	1,139	237,574	$2,502,033
2024	1,560	310,781	$4,343,672

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	39	86	$1,733
2016	22	57	$78,543
2017	29	88	$54,243
2018	100	623	$302,074
2019	132	746	$673,954
2020	125	666	$1,409,417
2021	120	330	$339,957
2022	213	733	$973,029
2023	245	828	$2,346,470
2024	323	1,234	$4,461,236

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	34	$3,529
2019	N/R	28	$3,870
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	226	240	$133
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	375	714	$96
96372	Injection of drug or substance under skin or into muscle	371	1,268	$10
36415	Insertion of needle into vein for collection of blood sample	897	2,090	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	834	2,089	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	82	2,086	$1,287,976
Jakafi	Ruxolitinib Phosphate	20	600	$348,753
Lenvima	Lenvatinib Mesylate	14	420	$308,105
Pomalyst	Pomalidomide	17	476	$308,088
Verzenio	Abemaciclib	18	504	$290,532

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	171	$3,895	Celgene Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ibrahim Ebada Sadek, M.D.?

Tedicare shows public-source Medicare data for Ibrahim Ebada Sadek, M.D. (NPI 1457672685), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ibrahim Ebada Sadek, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Ibrahim Ebada Sadek, M.D.?

Ibrahim Ebada Sadek, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Ibrahim Ebada Sadek, M.D. have Open Payments data?

Ibrahim Ebada Sadek, M.D. has 171 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.